Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2412, doi. 10.1111/dom.15560

By:

• Christofides, Elena A.;
• Puente, Orlando;
• Norwood, Paul;
• Denham, Douglas;
• Maheshwari, Hiralal;
• Lillestol, Michael;
• Hart, Terence;
• Nakhle, Samer;
• Chadha, Anurekha;
• Fitz‐Patrick, David;
• Sugimoto, Danny;
• Soufer, Joseph;
• Young, Douglas;
• Warren, Mark;
• Huffman, David;
• Reed, John;
• Bays, Harold;
• Arora, Samir;
• Rizzardi, Barbara;
• Tidman, Raymond

Publication type:

Article